Seres Therapeutics (MCRB) Tops Q2 EPS by 277c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of $0.47, $2.77 better than the analyst estimate of ($2.30). Revenue for the quarter came in at $736 thousand versus the consensus estimate of $358 thousand.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
• Ladybug Resource Group updates M&A program, holds early financing talks